Shares in United Therapeutics (NSDQ:UTHR) fell -7% this morning to $126.17 apiece after the company said that the U.S. commercial launch of Remosynch, Medtronic‘s (NYSE:MDT) implantable infusion pump for Remodulin, will be delayed until 2018.
In March, the FDA updated Medtronic’s Class I recall for the company’s SynchroMed II and EL implantable drug pumps over a priming bolus issue. which Medtronic said it can fix with a software update. But analysts are concerned that any delay in debuting an alternative delivery option for Remodulin will make it harder for United to protect its sales as it faces generic competition in the year ahead.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic’s infusion pump problems delay United’s Remosynch launch until 2018 appeared first on MassDevice.
from MassDevice http://ift.tt/2nwkX5x
Cap comentari:
Publica un comentari a l'entrada